Institutional shares held 54.6 Million
29.8K calls
13.4K puts
Total value of holdings $109M
$59K calls
$26K puts
Market Cap $165M
82,563,904 Shares Out.
Institutional ownership 66.15%
# of Institutions 140


Latest Institutional Activity in ALEC

Top Purchases

Q2 2025
Price T Rowe Associates Inc Shares Held: 4.88M ($9.75M)
Q2 2025
Eversept Partners, LP Shares Held: 1.99M ($3.97M)
Q2 2025
Adar1 Capital Management, LLC Shares Held: 1.72M ($3.45M)
Q2 2025
Acadian Asset Management LLC Shares Held: 2.17M ($4.34M)
Q2 2025
Citadel Advisors LLC Shares Held: 552K ($1.1M)

Top Sells

Q2 2025
Jane Street Group, LLC Shares Held: 24K ($47.9K)
Q2 2025
Diadema Partners LP Shares Held: 266K ($532K)
Q2 2025
Deutsche Bank Ag\ Shares Held: 990K ($1.98M)
Q2 2025
Dimensional Fund Advisors LP Shares Held: 383K ($767K)
Q2 2025
Aqr Capital Management LLC Shares Held: 407K ($813K)

About ALEC

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.


Insider Transactions at ALEC

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.72M Shares
From 11 Insiders
Grant, award, or other acquisition 1.72M shares
Sell / Disposition
408K Shares
From 6 Insiders
Open market or private sale 408K shares

Track Institutional and Insider Activities on ALEC

Follow Alector, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ALEC shares.

Notify only if

Insider Trading

Get notified when an Alector, Inc. insider buys or sells ALEC shares.

Notify only if

News

Receive news related to Alector, Inc.

Track Activities on ALEC